A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC).

Karen Anne Cadoo,Michael L. Meyers,Robert A. Burger,Deborah Kay Armstrong,Richard T. Penson,Michael S. Gordon,Gini F. Fleming,John W. Moroney,Erika Paige Hamilton,Linda R. Duska,Robert M. Wenham,Serap Sankoh,Susan Brouwer,Peter Ordentlich,Carol Aghajanian,Ursula A. Matulonis

A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC).

2019

Karen Anne Cadoo
Michael L. Meyers
Robert A. Burger
Deborah Kay Armstrong
Richard T. Penson
Michael S. Gordon
Gini F. Fleming
John W. Moroney
Erika Paige Hamilton
Linda R. Duska
Robert M. Wenham
Serap Sankoh
Susan Brouwer
Peter Ordentlich
Carol Aghajanian
Ursula A. Matulonis

5511Background: Preclinical evidence suggests that combining avelumab (A), a human anti-PD-L1 monoclonal antibody, and entinostat (E), a class I selective histone deacetylase (HDAC) inhibitor, may ...

Keywords:

Placebo
Avelumab
Randomized controlled trial
Pathology
Ovarian cancer
Entinostat
Oncology
Internal medicine
Medicine
in patient
epithelial ovarian cancer
Monoclonal antibody
Histone deacetylase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations